Kiniksa Pharmaceuticals (KNSA) News Today

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Gap Up to $24.49

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) have received an average recommendation of "Buy" from the four ratings firms that are currently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a buy rating. The average 1 year

Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a report on Friday. They set a "buy" rating and a $40.00 price objective for the company.

Los Angeles Capital Management LLC lessened its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 43.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 79,200 shares of the co

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Down 3.2%

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Hits New 1-Year High at $27.92

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 1-Year High at $27.96

Hennion & Walsh Asset Management Inc. grew its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 45.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 181,966 shares of the company's st

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 4,510,000 shares, an increase of 14.5% from the July 15th total of 3,940,000 shares. Based on an average daily trading volume, of 462,600 shares, the days-to-cover ratio is presently 9.7 days.

SG Americas Securities LLC grew its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 261.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 69,226 shares of the company's s

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) was the recipient of a large decrease in short interest during the month of July. As of July 15th, there was short interest totalling 3,940,000 shares, a decrease of 13.6% from the June 30th total of 4,560,000 shares. Based on an average trading volume of 456,400 shares, the days-to-cover ratio is presently 8.6 days.

Sei Investments Co. bought a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 73,481 shares of the company's stock, valued

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Stock analysts at Wedbush boosted their Q3 2024 earnings per share estimates for shares of Kiniksa Pharmaceuticals in a research note issued to investors on Tuesday, July 23rd. Wedbush analyst D. Nierengarten now expects that the company

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading 6.6% Higher

Acadian Asset Management LLC boosted its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 167.8% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 164,568 shares of the company's stock after purchasing an additional 103,120 share

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative return on equity of 7.26% and a net margin of 2.78%. The business had revenue of $108.30 million for the quarter, compared to analyst estimates of $90.60 million. During the same quarter in the prior year, the company earned ($0.02) earnings per share. The company's revenue was up 51.5% on a year-over-year basis.

Wedbush raised their price target on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an "outperform" rating in a research note on Tuesday.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 52-Week High at $23.24

BNP Paribas Financial Markets trimmed its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 39.9% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 46,060 shares of the company's stock after selling 30,608 share

Kiniksa Pharmaceuticals (NASDAQ:KNSA) will be releasing earnings before the market opens on Tuesday, July 23, Zacks reports.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 12-Month High at $22.12

Nordea Investment Management AB bought a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 126,742 shares of the company's stock,

Parkman Healthcare Partners LLC increased its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 20.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 615,693 shares of the company's stock after

ADAR1 Capital Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 105,000 shares of the company's st

Rafferty Asset Management LLC lessened its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 31.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 95,855 shares of the company's stock after selling 43,251